What is the recommended treatment for tinea corporis (ringworm)?

Treatment of Ringworm (Tinea Corporis)

First-Line Treatment: Topical Antifungals

For localized tinea corporis in immunocompetent patients, apply topical allylamine antifungals (terbinafine 1% or naftifine 1%) once daily for 1-2 weeks as first-line therapy. 1

Why Allylamines Over Azoles

• Allylamines require shorter treatment duration (1-2 weeks) compared to azoles (2-4 weeks), improving compliance 1, 2
• Terbinafine demonstrates fungicidal activity and is FDA-approved for tinea corporis 3
• Naftifine 1% achieves significantly higher mycological cure rates versus placebo (RR 2.38, NNT 3) 4

Alternative Topical Agents

• Azoles (clotrimazole or miconazole): Apply twice daily for 2-4 weeks if allylamines are unavailable 4
• Clotrimazole 1% shows mycological cure rates superior to placebo (RR 2.87, NNT 2) 4
• Continue treatment for at least one week after clinical clearing to prevent relapse 2

When to Use Oral Antifungals

Switch to oral therapy when infection is extensive, resistant to topical treatment, or the patient is immunocompromised. 1

Oral Treatment Options

• Terbinafine 250 mg daily for 1-2 weeks is first-line oral therapy, achieving 87.1% mycological cure at 6 weeks 1
• Itraconazole 100 mg daily for 15 days is an alternative, with 87% mycological cure rate (superior to griseofulvin's 57%) 4, 1
• Terbinafine shows particular superiority against Trichophyton tonsurans infections 4, 1

Pre-Treatment Monitoring

• Obtain baseline liver function tests before initiating terbinafine or itraconazole, especially if pre-existing hepatic abnormalities exist 4

Diagnostic Confirmation

Confirm diagnosis with potassium hydroxide (KOH) preparation or fungal culture before treatment to identify the causative organism. 1

• Collect specimens via scalpel scraping, hair pluck, brush, or swab as appropriate 4
• Clinical diagnosis alone is unreliable—tinea corporis mimics eczema and other dermatoses 5

Treatment Endpoint and Follow-Up

Mycological cure (negative microscopy/culture), not just clinical improvement, defines treatment success. 1

• Repeat mycology sampling until clearance is documented 4, 1
• Clinical appearance can be misleading—continue therapy until mycological confirmation 4

Prevention of Recurrence

Screen and treat all household contacts, as over 50% of family members may harbor anthropophilic species like T. tonsurans. 1

• Avoid skin-to-skin contact with infected individuals and keep lesions covered 1
• Do not share towels, combs, brushes, or personal items 4, 1
• Clean all fomites with disinfectant or 2% sodium hypochlorite solution 4, 1

Common Pitfalls to Avoid

• Do not use griseofulvin as first-line therapy—it requires longer duration and has lower efficacy than terbinafine 4
• Do not use topical antifungal-steroid combinations routinely—while they may accelerate clinical clearing (RR 0.67 for clinical cure), they carry risk of skin atrophy and do not improve mycological cure rates (RR 0.99) 4, 5
• Do not discontinue therapy based solely on symptom resolution—continue until mycological cure is confirmed 1
• Do not overlook household contacts—failure to screen and treat leads to reinfection 1

Treatment Failure Management

• Assess for non-compliance, suboptimal absorption, organism resistance, or reinfection from untreated contacts 4
• If clinical improvement occurs but mycology remains positive, extend current regimen 2-4 weeks 4
• If no clinical improvement, switch to alternative oral agent immediately 4